IpsenIPSEF 95 Net Margin % is 5.50% as of Dec. 2025, which is 64% below its 10-year median of 15.07. GuruFocus rates IPSEF with a GF Score™ of 95/100 and a GF Value™ of $92.81. The stock has 7 warning signs investors should review. Among 956 Drug Manufacturers companies, Ipsen ranks better than 67.99% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Ipsen's Net Income for the
six
months ended in Dec. 2025 was $128 Mil. Ipsen's Revenue for the
six
months ended in Dec. 2025 was $2,333 Mil. Therefore, Ipsen's net margin for the quarter that ended in Dec. 2025 was 5.50%.
The historical rank and industry rank for Ipsen's Net Margin % or its related term are showing as below:
IPSEF'
s Net Margin % Range Over the Past 10 Years
Min: -1.88 Med: 15.07 Max: 23.52
Current: 11.29
IPSEF's Net Margin % is ranked better than 67.99% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs IPSEF: 11.29
Ipsen (OTCPK:IPSEF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Ipsen Net Margin % Related Terms
Ipsen Net Margin % Historical Data
* Premium members only.
The historical data trend for Ipsen's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipsen Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipsen's Net Margin % distribution charts can be found below:
* The bar in red indicates where Ipsen's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ipsen (IPSEF) has a Net Margin % of 5.50% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Ipsen and its competitors. This is 64% below median its historical median of 15.07. According to the industry distribution chart, Ipsen ranks #306 out of 956 companies in the Drug Manufacturers industry, placing it in the top 32%.
Is Ipsen's Net Margin % too high?
Ipsen's current Net Margin % of 5.50% is 64% below median its 10-year median of 15.07. The Drug Manufacturers industry median Net Margin % is 5.56. Ipsen's value of 5.50% is 1.1% below this industry median. Based on the distribution chart, Ipsen ranks #306 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ipsen has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Ipsen's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ipsen ranks #306 out of 956 companies for Net Margin %. This puts Ipsen in the upper half of its industry. The industry median Net Margin % is 5.56. Ipsen's value of 5.50% is 1.1% below this benchmark. While the company's 10-year median is 15.07 vs. the industry median of 5.56, Ipsen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipsen's current Net Margin % of 5.50% is 1.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Ipsen and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipsen's current Net Margin % is 5.50%, which is 64% below median its own 10-year median of 15.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Ipsen (IPSEF) has a current Net Margin % of 5.50%. The stock's GF Value™ is $92.81, compared to a current price of $113.13 — trading 21.9% above its estimated fair value. The current Net Margin % is 5.50%, which is 64% below median its 10-year median of 15.07 and 1.1% below the Drug Manufacturers industry median of 5.56. Ipsen's overall GF Score™ is 95/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Ipsen (IPSEF), the current Net Margin % is 5.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipsen (IPSEF) Overvalued in 2026?
Based on GuruFocus' analysis, Ipsen stock appears to be overvalued.
The current stock price of $113.13 is trading 21.9% above its estimated GF Value™ of $92.81.
Key valuation signals for IPSEF:
Net Margin %: 5.50% (64% below median its 10-year median of 15.07)
GF Value™: $92.81 vs. price of $113.13 (21.9% above fair value)
Industry Position: 1.1% below the Drug Manufacturers median (#306 of 956)
No single metric tells the full story. See the IPSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
95GF Score
Get the complete analysis for IPSEF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPSEF has been successfully added to your 
